Pembrolizumab plus lenvatinib for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have cervical cancer that is confirmed by pathology (tissue testing).
- Your cancer is locally advanced or has spread (metastatic), and it has either progressed or caused intolerance to at least one prior treatment.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to effective birth control during treatment and for at least 120 days after the last dose.
- Your cancer has “measurable” spots on scans, meaning doctors can track them over time (including certain spots in previously radiated areas if they clearly worsened).
- You can provide tumor tissue (from a recent biopsy or archived sample) for lab testing.
- Your general health is good enough for treatment, such as ECOG performance status 0–1, with required blood counts and organ/liver/kidney/clotting tests within the allowed ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs for people with advanced cervical cancer that has come back or spread, and who have already tried standard treatments. It aims to see if adding these experimental drugs to lenvatinib is safe and effective.
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
This trial tests whether adding two drugs (pembrolizumab and lenvatinib) to standard chemoradiation and brachytherapy can improve outcomes for people with high-risk locally advanced cervical cancer. It is designed for patients who are fit enough to undergo intensive treatment.
This trial tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for women with advanced vulvar cancer that cannot be surgically removed or has spread. The goal is to see if this combination can shrink or control the cancer.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.